TY - JOUR
T1 - Recommendations for detection, validation, and evaluation of RNA editing events in cardiovascular and neurological/neurodegenerative diseases
AU - Karagianni, Korina
AU - Bibi, Alessia
AU - Madé, Alisia
AU - Acharya, Shubhra
AU - Parkkonen, Mikko
AU - Barbalata, Teodora
AU - Srivastava, Prashant K
AU - de Gonzalo-Calvo, David
AU - Emanueli, Constanza
AU - Martelli, Fabio
AU - Devaux, Yvan
AU - Dafou, Dimitra
AU - Nossent, A Yaël
AU - EU-CardioRNA COST Action CA17129
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2024/3/12
Y1 - 2024/3/12
N2 - RNA editing, a common and potentially highly functional form of RNA modification, encompasses two different RNA modifications, namely adenosine to inosine (A-to-I) and cytidine to uridine (C-to-U) editing. As inosines are interpreted as guanosines by the cellular machinery, both A-to-I and C-to-U editing change the nucleotide sequence of the RNA. Editing events in coding sequences have the potential to change the amino acid sequence of proteins, whereas editing events in noncoding RNAs can, for example, affect microRNA target binding. With advancing RNA sequencing technology, more RNA editing events are being discovered, studied, and reported. However, RNA editing events are still often overlooked or discarded as sequence read quality defects. With this position paper, we aim to provide guidelines and recommendations for the detection, validation, and follow-up experiments to study RNA editing, taking examples from the fields of cardiovascular and brain disease. We discuss all steps, from sample collection, storage, and preparation, to different strategies for RNA sequencing and editing-sensitive data analysis strategies, to validation and follow-up experiments, as well as potential pitfalls and gaps in the available technologies. This paper may be used as an experimental guideline for RNA editing studies in any disease context.
AB - RNA editing, a common and potentially highly functional form of RNA modification, encompasses two different RNA modifications, namely adenosine to inosine (A-to-I) and cytidine to uridine (C-to-U) editing. As inosines are interpreted as guanosines by the cellular machinery, both A-to-I and C-to-U editing change the nucleotide sequence of the RNA. Editing events in coding sequences have the potential to change the amino acid sequence of proteins, whereas editing events in noncoding RNAs can, for example, affect microRNA target binding. With advancing RNA sequencing technology, more RNA editing events are being discovered, studied, and reported. However, RNA editing events are still often overlooked or discarded as sequence read quality defects. With this position paper, we aim to provide guidelines and recommendations for the detection, validation, and follow-up experiments to study RNA editing, taking examples from the fields of cardiovascular and brain disease. We discuss all steps, from sample collection, storage, and preparation, to different strategies for RNA sequencing and editing-sensitive data analysis strategies, to validation and follow-up experiments, as well as potential pitfalls and gaps in the available technologies. This paper may be used as an experimental guideline for RNA editing studies in any disease context.
KW - A-to-I editing
KW - C-to-U editing
KW - cardiovascular disease
KW - methodology
KW - MT: RNA/DNA editing
KW - neurodegenerative disease
KW - neurovascular disease
KW - RNA editing
UR - http://www.scopus.com/inward/record.url?scp=85186893878&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38192612
U2 - 10.1016/j.omtn.2023.102085
DO - 10.1016/j.omtn.2023.102085
M3 - Review article
C2 - 38192612
SN - 2162-2531
VL - 35
JO - Molecular Therapy - Nucleic Acids
JF - Molecular Therapy - Nucleic Acids
IS - 1
M1 - 102085
ER -